Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Positioned for Accelerated Development with a CAGR of 7.2% Through 2034, DelveInsight Finds

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market was valued at approximately USD 1.8 billion in 2023 and is projected to grow at a robust CAGR of 7.2% during the forecast period (2024–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the CIDP landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The CIDP market is increasingly guided by innovative therapeutic approaches. FcRn inhibitors represent a highly lucrative emerging segment, highlighted by promising treatments like VYVGART HYTRULO. The approval of VYVGART HYTRULO last year by the US FDA has marked a significant advancement in the therapeutic landscape, offering a convenient at-home self-injection option for CIDP patients.

DelveInsight's report, "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast- 2034," provides a comprehensive analysis of the CIDP landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines CIDP market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Chronic Inflammatory Demyelinating Polyneuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, click here: Chronic Inflammatory Demyelinating Polyneuropathy Market Forecast 

Some of the key facts of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report:

• Key Chronic Inflammatory Demyelinating Polyneuropathy Companies: Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Takeda Pharmaceuticals, Pfizer, CSL Behring, Octapharma, and others
• Key Chronic Inflammatory Demyelinating Polyneuropathy Therapies: VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), Riliprubart (SAR445088), Nipocalimab (JNJ-80202135), Batoclimab (HL161), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), PRIVIGEN, PANZYGA, and others
• The Chronic Inflammatory Demyelinating Polyneuropathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Inflammatory Demyelinating Polyneuropathy pipeline products will significantly revolutionize the Chronic Inflammatory Demyelinating Polyneuropathy market dynamics.

Chronic Inflammatory Demyelinating Polyneuropathy Overview

Chronic Inflammatory Demyelinating Polyneuropathy is a rare neurological disorder characterized by inflammation and damage to the protective covering of nerves, known as the myelin sheath. This damage disrupts the communication between nerves and muscles, leading to progressive weakness and impaired sensory function. CIDP is clinically classified into typical and atypical forms. The typical form, the most common, involves symmetrical polyneuropathy, where both proximal and distal muscles are equally affected, leading to widespread weakness and sensory deficits. Symptoms usually progress gradually, but severity varies among patients, impacting walking, fine motor skills, and daily activities.

Atypical CIDP includes variants like Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM), or asymmetric CIDP, where nerve damage is localized rather than symmetrical. Another variant, Distal Acquired Demyelinating Symmetric Neuropathy (DADS), affects the lower limbs and progresses more slowly. CIDP may also affect only motor or sensory nerves. The prognosis of CIDP largely depends on early diagnosis and timely treatment. Many patients respond positively to immunomodulatory therapies, resulting in significant improvement or even remission. However, some cases may become resistant to treatment, resulting in ongoing disability.

Key Trends in Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market:

• Rising Adoption of FcRn Inhibitors: Increasing use of FcRn inhibitors such as efgartigimod alfa and batoclimab for reducing harmful IgG antibodies in CIDP.
• Immunotherapy Expansion: Growing uptake of complement pathway inhibitors and immunomodulatory therapies for improved patient outcomes.
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics enabling personalized treatment strategies based on disease subtypes.
• Pipeline Innovation: Development of next-generation monoclonal antibodies, complement inhibitors, and combination therapies to overcome treatment resistance.
• Subcutaneous Administration: Shift towards subcutaneous formulations offering convenience and improved patient compliance.
• Digital Health Integration: Use of telemedicine and remote monitoring to optimize treatment and patient outcomes.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology

The report section on Chronic Inflammatory Demyelinating Polyneuropathy epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes gender- and age-specific distribution, regional and global trends, and data on key clinical subtypes such as typical CIDP and atypical CIDP. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of CIDP and plan targeted interventions, research, and treatment strategies.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation:

The Chronic Inflammatory Demyelinating Polyneuropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Diagnosed Prevalent Cases of CIDP
• Gender-specific Diagnosed Prevalent Cases of CIDP
• Age-specific Diagnosed Prevalent Cases of CIDP
• Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP
• Refractory Cases of CIDP

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Forecast 

Recent Development In The CIDP Treatment Landscape:

• In April 2025, Argenx announced FDA approval of a prefilled syringe option for self-injection of VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This advancement provides patients with an enhanced convenience factor for maintaining remission through subcutaneous administration.
• In June 2025, CAPTIVATE clinical trial initiated to evaluate DNTH103, a potential therapy for CIDP patients.
• In June 2025, the European Commission approved efgartigimod (Vyvgart Hytrulo) for CIDP following positive Phase 3 results, marking a step forward for targeted therapies.
• In March 2025, Immunovant, Inc. reported topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory demyelinating polyneuropathy (CIDP). These results are expected to guide the design of future trials and regulatory approval pathways for CIDP therapies.

Chronic Inflammatory Demyelinating Polyneuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Inflammatory Demyelinating Polyneuropathy market or expected to get launched during the study period. The analysis covers CIDP market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Inflammatory Demyelinating Polyneuropathy Therapies and Key Companies

• Riliprubart (SAR445088): Sanofi
• Nipocalimab (JNJ-80202135): Janssen Research and Development
• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
• HYQVIA: Takeda
• GAMMAGARD LIQUID/KIOVIG: Takeda
• PRIVIGEN: CSL Behring
• PANZYGA: Pfizer and Octapharma

To know more about Chronic Inflammatory Demyelinating Polyneuropathy companies working in the treatment market, visit @ Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials and Therapeutic Assessment 

Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers

• Increasing prevalence of CIDP globally, driving demand for effective therapies
• Growth of FcRn inhibitors and immunomodulatory therapies for immune-mediated CIDP management
• Advancements in molecular diagnostics and biomarker testing enabling precision medicine
• Rising healthcare expenditure and government initiatives supporting neurological disease care
• Expanding awareness and early diagnosis through improved diagnostic capabilities
• Development of subcutaneous therapies improving patient compliance and convenience
• Expansion of diagnostic capabilities through nerve conduction studies, electromyography, and advanced imaging

Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers

• High cost of biologic therapies and immunoglobulins limiting patient access
• Complex clinical trial designs and lengthy regulatory approval processes
• Resistance development to existing treatments reducing long-term efficacy
• Limited awareness and accessibility in emerging markets
• Side effects and safety concerns associated with long-term immunosuppressive therapies
• Variability in patient response due to genetic and immune factors
• Diagnostic challenges leading to potential misdiagnosis of CIDP

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Chronic Inflammatory Demyelinating Polyneuropathy Companies: Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Takeda Pharmaceuticals, Pfizer, CSL Behring, Octapharma, and others
• Key Chronic Inflammatory Demyelinating Polyneuropathy Therapies: VYVGART HYTRULO, HYQVIA, Riliprubart (SAR445088), Nipocalimab (JNJ-80202135), Batoclimab (HL161), GAMMAGARD LIQUID/KIOVIG, PRIVIGEN, PANZYGA, and others
• Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment: CIDP current marketed and emerging therapies
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: CIDP market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs, KOL's views, Analyst's views, Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement

Discover more about therapies set to grab major Chronic Inflammatory Demyelinating Polyneuropathy market share @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market